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Abstract
Background: Narcolepsy causes dramatic behavioral alterations in both humans and dogs, with
excessive sleepiness and cataplexy triggered by emotional stimuli. Deficiencies in the hypocretin
system are well established as the origin of the condition; both from studies in humans who lack
the hypocretin ligand (HCRT) and in dogs with a mutation in hypocretin receptor 2 (HCRTR2).
However, little is known about molecular alterations downstream of the hypocretin signals.
Results: By using microarray technology we have screened the expression of 29760 genes in the
brains of Doberman dogs with a heritable form of narcolepsy (homozygous for the canarc-1
[HCRTR-2-2] mutation), and their unaffected heterozygous siblings. We identified two
neuropeptide precursor molecules, Tachykinin precursor 1 (TAC1) and Proenkephalin (PENK), that
together with Suppressor of cytokine signaling 2 (SOCS2), showed reduced expression in
narcoleptic brains. The difference was particularly pronounced in the amygdala, where mRNA
levels of PENK were 6.2 fold lower in narcoleptic dogs than in heterozygous siblings, and TAC1 and
SOCS2 showed 4.4 fold and 2.8 fold decrease in expression, respectively. The results obtained from
microarray experiments were confirmed by real-time RT-PCR. Interestingly, it was previously
shown that a single dose of amphetamine-like stimulants able to increase wakefulness in the dogs,
also produce an increase in the expression of both TAC1 and PENK in mice.
Conclusion: These results suggest that TAC1, PENK and SOCS2 might be intimately connected
with the excessive daytime sleepiness not only in dogs, but also in other species, possibly including
humans.
Background
Narcolepsy is a sleep disorder found in several mammal
species [1]. The human form of narcolepsy is caused by an
interplay of genetic and environmental factors and appear
mostly in sporadic cases [2]. Canine narcolepsy was first
reported in the 1970's, and since then dogs have been
extensively used for exploring the underlying mechanisms
of the disease [3]. A colony of Doberman pinschers with a
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heritable form of narcolepsy due to a mutation in a single
major gene was established at Stanford Sleep Research
Center in 1976 [4]. The genetic transmission of the muta-
tion, also known as canarc-1, is autosomal recessive.
Homozygous individuals show several symptoms similar
to the human form of narcolepsy including emotionally
triggered cataplexy (sudden loss of muscle tone), short
sleep latency and fragmented sleep [5,6]. Linkage analysis
and subsequent positional cloning experiments identified
the canarc-1 to be hypocretin receptor 2 (HCRTR2) [7].
This finding was rapidly followed by findings in human
narcolepsy where hypocretin ligand deficiency was found
in most narcolepsy-cataplexy cases [8,9]. Impairment in
the hypocretin system is well established as the origin of
the condition, but little is known about the downstream
molecular alterations that may lead to the phenotypes
related to narcolepsy. This knowledge will be essential to
link the alterations in dogs with possible alterations in
humans that lead to similar symptoms. To identify genes
with expression affected by the mutated hypocretin recep-
tor in dogs, we compared gene expression patterns in
three parts of the brains using human microarrays con-
taining 29760 clones in a cross-species hybridization
design previously shown successful [10,11]. We studied
the expression pattern in brain tissue samples from
hypothalamus, amygdala and pons of six narcoleptic
Doberman dogs compared to their six healthy hetero-
zygous siblings. Since all animals were raised in the same
environmental conditions and have a very similar genetic
background, our experiment offers a unique opportunity
to identify molecular pathways that have been altered in
narcolepsy in the absence of large environmental varia-
bles that modify mRNA expression levels.
Results
Microarray analysis
To assess whether brain gene expression differed between
narcoleptic and heterozygous dogs, we compared the rel-
ative mRNA levels in pools of narcoleptic and hetero-
zygous siblings in three regions of the brain, using eight
cDNA microarrays. Of the total number of 29760 cDNA
clones on the array, 15227 gave a signal above back-
ground in amygdala, pons and hypothalamus, indicating
that about 50% of the clones on the arrays cross-hybrid-
ized with mRNA expressed in all three regions of the dog
brain. The cDNA clones were ranked after their likelihood
of indicating an average mRNA expression difference
between the narcoleptic animals and the control group
that was not due to random technical variation (Figure 2,
Table 1). Twenty-two cDNA clones, with a penalized F-
ratio larger than 5, showed consistent average expression
differences between the groups, although the differences
were small for several hybridizations (Table 1). Of these
22 selected clones, we expected five false positives (30%)
to occur by chance according to our permutation analysis.
Brain expression differences between pools of narcoleptic  and heterozygous dogs, determined by microarray analysis Figure 2
Brain expression differences between pools of nar-
coleptic and heterozygous dogs, determined by 
microarray analysis. Average differences in gene expres-
sion between six narcoleptic dogs and six unaffected siblings, 
heterozygous for the canarc-1 mutation, for three regions of 
the brain. For each of the 29 760 human cDNA clones both 
the average expression difference (M) and the ranking statis-
tic (penalized F-ratio) is shown for pair-wise comparisons. 
Twenty two clones with a penalized F-ratio above five 
(marked in black) showed a significant expression difference 
between narcoleptic and heterozygous individuals (false dis-
covery rate, FDR < 0.29).
Pedigree of Doberman dogs carrying the canarc-1 mutation Figure 1
Pedigree of Doberman dogs carrying the canarc-1 
mutation. Homozygous individuals indicated by filled sym-
bols and unaffected heterozygotes with dotted symbols 
(females as circles, males as squares). Individuals included in 
brain gene expression analysis indicated by stars. Pedigree 
adapted from Riehl et al [52].
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Since the microarray screening was associated with a rela-
tively large proportion of expected false positives (due to
technical variation and small expression differences), and
due to that fact that inter-individual variation in mRNA
levels was not taken into account because of the pooling
procedure used, the results from the microarrays are only
suggestive. Consequently, these results were confirmed by
an independent method at the individual level as
described below. The microarray data (accession number
E-MEXP-1076) is available through ArrayExpress.
Real-time RT-PCR
From the microarray list (Table 1), we selected genes for
qPCR verification with evidence of a transcriptional
change larger or equal to 1.6 fold in at least one of the
examined regions. The rational for focusing on relatively
large effects was that the technical variation associated
with qPCR makes it difficult to verify true expression dif-
ferences of limited magnitude, and we also reasoned that
the biological significance of any findings would be
related to the magnitude of the disturbance. For 8 of the
10 genes that fulfilled the selection criteria (underlined in
Table 1) we were able to design qPCR primers for an
orthologous gene in dog. For the remaining two genes, no
corresponding sequence was available in the dog EST
databases, and it was therefore not possible to design dog
primers. Since the dog genome has been sequenced but
not yet fully annotated, several mRNA sequences are only
predicted annotations to known genes in other species.
However, all primers were designed to amplify a gene-spe-
cific mRNA sequence from dog, and according to BLAST
searches with the dog primer sequences, no cross-amplifi-
cation of other members of the same gene families should
be possible.
For each individual animal, mRNA levels for the corre-
sponding dog EST's were quantified in the three brain
regions. The mean mRNA levels of three genes,
Proenkephalin (PENK), Tachykinin precursor 1 (TAC1)
and Suppressor of cytokine signaling 2 (SOCS2) were
lower in the brains of narcoleptic dogs than in their heter-
ozygous siblings (PENK p = 0.001, TAC1 p < 0.001 and
SOCS2 p = 0.001) (Figure 3). As shown in the figure, the
effect was most pronounced in the amygdala. This was
Table 1: Expression difference between pools of six narcoleptic dogs and six unaffected siblings, heterozygous for the canarc-1 
mutation. Similarity scores (right-most column) between the human gene and the dog orthologue was retrieved from Ensembl v39 
(June 2006) and aligned with BLAST (bl2seq).
Clone ID Symbol Name PenF ratio p-value A H P Similarity (%)
2017204 PENK Proenkephalin 11.0 0.0008 -1.36 -0.09 -0.39 87
784179 TAC1 Tachykinin, precursor 1 8.7 0.0025 -1.20 -0.05 -0.44 96
430318 PVALB Parvalbumin 8.3 0.0044 +0.51 +0.91 +0.28 90
824643 CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 
2, beta
7.0 0.0034 -0.49 -0.57 -0.44 92
782789 AVPR1A Arginine vasopressin receptor 1A 6.3 0.0019 -0.70 -0.21 -0.48 88
843426 SAV1 Salvador homolog 1 (Drosophila) 6.1 0.0022 +0.66 +0.07 +0.64 95
853956 ARIH2 Ariadne homolog 2 (Drosophila) 5.9 0.0064 -0.25 -0.68 -0.48 94
1848986 PCYT1B Phosphate cytidylyltransferase 1, choline, beta isoform 5.7 0.0104 -0.34 -0.56 -0.54 93
825265 POLD3 Polymerase (DNA-directed), delta 3, accessory 
subunit
5.7 0.0068 +0.45 +0.33 +0.61 90
1535596 RDH11 DKFZP564M1462 protein 5.6 0.0050 -0.40 -0.30 -0.65 88
838504 SMBP SM-11044 binding protein 5.5 0.0066 +0.66 +0.28 +0.42 95
1046495 N/A # 5.5 0.0016 +0.02 -0.85 -0.44 Not found
646753 FLJ38736 Hypothetical protein FLJ38736 5.3 0.0045 -0.47 -0.13 -0.70 87
896949 HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 5.2 0.0066 +0.44 +0.30 +0.56 92
287646 RNF14 Ring finger protein 14 5.1 0.0085 +0.40 -1.62 -0.09 93
1506399 N/A * 5.1 0.0091 -0.52 -0.02 -0.77 Not found
796885 RPL23 Ribosomal protein L23 5.0 0.0063 +0.74 -0.05 +0.59 Not found
45452 N/A † 5.0 0.0308 -0.33 -0.49 -0.74 Not found
898222 ATPAF2 ATP synthase mitochondrial F1 complex assembly 
factor 2
4.9 0.0209 -0.38 -0.36 -0.68 88
131073 SOCS2 Suppressor of cytokine signaling 2 4.8 0.0044 -0.79 -0.16 -0.27 97
308231 MYO1B Myosin IB 4.8 0.0049 -0.56 -0.30 -0.37 92
448708 GAPVD1 GTPase activating protein and VPS9 domains 1 4.6 0.0106 +0.58 +0.12 +0.55 Not found
The eight underlined genes have been also tested with qPCR. Average differences between narcoleptics and controls larger than a log2 value 
corresponding to 0.7 (1.6 fold) are also underlined. N/A = not annotated in the clone database.
# Transcribed locus, moderately similar to NP_002645.3 pyruvate kinase 3 isoform 1; thyroid hormone-binding protein, cytosolic; PK, muscle type; 
OPA-interacting protein 3 (Homo sapiens)
* Amino acid sequence 100% similarity to Myomesin2
† Clone mapping to two Unigene clusters, Hs.435948 and Hs.524395BMC Neuroscience 2007, 8:34 http://www.biomedcentral.com/1471-2202/8/34
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also evident from the analysis, indicated by a significant
interaction between brain region and disease status for
two of the genes (the p-value for the interaction was
0.037, 0.047 and 0.057 for PENK,  TAC1  and  SOCS2
respectively). In the amygdala, the mRNA levels of PENK
was 6.2 fold lower in narcoleptic dogs than in hetero-
zygous siblings, whereas TAC1 and SOCS2 showed a 4.4
fold and 2.8 fold decrease in expression respectively.
Thus, we were able to confirm expression differences of
three of the eight selected genes. For the remaining five,
they may have represented false positive results from the
arrays. Alternatively, we may not have selected the correct
orthologous gene in dogs, which may be particularly
likely for clones that were not properly annotated
(1046495 and 646753) or belong to large gene families
(RNF14 and AVPR1A).
Discussion
We have compared brain gene expression between nar-
coleptic dogs and their healthy heterozygous siblings and
identified three genes, TAC1, PENK and SOCS2, with a
down-regulated expression profile, especially pronounced
in amygdala and pons, in the brain of narcoleptic dogs.
We used cross-species hybridizations of pools of dog
mRNA to human microarrays. Cross-species hybridiza-
tions can be very useful when well annotated and vali-
dated microarrays are available in other species, such as
humans, or when the genome of the species under study
is poorly known [12,13], and the method is sufficiently
sensitive for identification of some genes with large
expression differences [14]. The investigated regions of
the brain, hypothalamus, amygdala and pons, were exam-
ined because the hypocretin containing neurons are
located in lateral hypothalamus, from where they project
to several areas of the brain [15]. Two of these projection
areas selected are the amygdala and pons, since several
investigators suggested that these structures play impor-
tant roles for the regulation of REM sleep and induction of
cataplexy in narcoleptic dogs [16-18].
A limitation of this study may be that all dogs have been
exposed to drug challenges, as explained in the Methods
section. This was done in the context of a linkage study to
confirm phenotypic status in backcross animals (Mignot
et al., 1993). We believe it is unlikely that drug history is
responsible for the observed expressional differences
between narcoleptics and heterozygotes. Both groups of
animals were treated in parallel with the exact same drugs
at the same doses and in the same sequence. Furthermore,
drug doses used were typically very low, exposure was
equal for all animals and rather limited in time, as a recov-
ery of 9 months without drugs was allowed.
For the initial scan we used cross-species hybridizations of
dog mRNA to human microarrays. In previous work, we
Expression differences between narcoleptic and hetero- zygous dogs, determined by qPCR Figure 3
Expression differences between narcoleptic and het-
erozygous dogs, determined by qPCR. Mean expres-
sion of A) PENK, B) TAC1 and C) SOCS2 in six narcoleptic 
dogs (black bars) and six unaffected siblings (grey bars) heter-
ozygous for the canarc-1 mutation with standard errors 
given. Narcoleptic individuals show an overall restricted 
expression pattern for the three genes (PENK p = 0.037, 
TAC1 p = 0.047 and SOCS2 p = 0.057), with most pro-
nounced effect in the amygdala.
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have repeatedly used this approach to successfully identify
genes that are differentially expressed in canids [10,11] as
dog and human transcripts have a relatively high
sequence homology, estimated to about 88% [11]. How-
ever, cross-species hybridization may have limited sensi-
tivity due to less stringent hybridization conditions, and
the method will bias the detection of expression differ-
ences towards abundant mRNA species with a conserved
sequence. It is thus possible that small alteration in the
activity of many genes down-stream of the hypocretin
receptor mutation were over-looked in our microarray
screening. On the other hand, it is possible that the altered
activity of a few key genes such as PENK, TAC1 and SOCS2
is crucial for the development of the disease.
TAC1 encodes four products of the tachykinin peptide
family: Substance P, Substance K, neurokinin A and neu-
ropeptide gamma [19]. The tachykinins interact with G-
protein coupled receptors and mediate biological func-
tions such as smooth muscle contraction, neuronal excita-
tion and pain transmission. Substance P is of special
interest, since it has shown to initiate and maintain REM
sleep in the reticular formation of the pons, and increase
paradoxical sleep (REM) latency and promote wakeful-
ness [20,21]. It has also been shown that Substance P con-
taining neurons project from the nuclei of the brainstem
to the amygdala [22]. A decrease expression of TAC1
could therefore, at least in pons, be responsible for a
decrease in substance P and a reduction of wakefulness
and an increase in REM sleep propensity.
The other down regulated neuropeptide precursor, PENK,
encodes a 267 amino acid precursor of two penta pep-
tides: met- and leu-enkephalin. Enkephalins, compete
with, and mimic the effect of opiate drugs, acting on opi-
oid receptors in the brain. Interestingly, it has been shown
that hypocretin neurons expresses mu-opioid receptors
[23], and that the PENK derivative [D-Ala, N-Me-Phe, Gly-
cinol]-enkephalin (DAMGO), activates G-proteins in
most REM-sleep related nuclei in the brain stem of rats
[24] and inhibits signalling of neurons in the amygdala
[25]. Also, another related opioid-like peptide, prodynor-
phin (PDYN), has shown to co-localize with HCRT in the
cells of the lateral hypothalamic area [26,27], and was
recently reported to have an inhibitory effect on hypocre-
tin neurons [28]. Furthermore, transgenic preroenkepha-
lin-knockout female mice have shown to display altered
emotional responses [29], and altered expression of PENK
has been associated with the dyskinetic movement in Par-
kinson patients [30]. Taken together, all of these results
suggest that the observed difference in PENK transcripts
also may be related to the behavioural and motor abnor-
malities seen in the narcoleptic dogs.
SOCS2, shown in this study to be down-regulated in nar-
coleptic dog amygdala, belongs to a family of genes whose
proteins acts as negative regulators in the JAK/STAT sign-
aling pathway of cytokine responses [31]. Cytokines pro-
duced by the immune system have previously been
suggested to be involved in sleep regulation [32] and
increased levels of the cytokines TNF-α and IL-6 have been
reported in human narcoleptic plasma samples as com-
pared to controls [33]. It is not known if the observed
decrease in SOCS2 expression in the narcoleptic dogs may
be associated with an increased cytokine response since an
involvement of immunological component is obscure in
the canine model of narcolepsy [6]. In addition to
cytokine signaling, SOCS2 is also known to be induced by
Growth hormone (GH) and to be a regulator of GH recep-
tor signaling [34,35]. Interestingly, human narcoleptic
patients are reported having an altered GH secretion pat-
tern [33,36] and hypocretins are found to inhibit GH
secretion in the brain cells of both rat and pig [37-39]. It
is therefore possible to hypothesize that SOCS2 expres-
sion in narcoleptic dogs is affected by a similar action of
GH secretion.
Conclusion
Presently there is no cure for narcolepsy, and available
treatments are purely symptomatic. Patients suffering
from severe daytime sleepiness are treated with ampheta-
mine-like stimulants (methylphenidate, dextro-ampheta-
mine, pemoline, methamphetamine or modafinil) to
increase wakefulness, vigilance, and performance [40].
Sleepiness in the canine narcolepsy model used in this
study can also be improved with amphetamine-like stim-
ulants [6], and mice treated with amphetamine-like stim-
ulants (e.g. Modafinil) increase their wake time [41].
Interestingly, a single dose of methamphetamine (or
methamphetamine in combination with valproate) has
shown to increase the expression of both TAC1 and PENK
together with dopamine- and cAMP-regulated phospho-
protein of 32 kDa (DARPP-32) in the prefrontal cortex of
mice [42]. Since amphetamine and modafinil are thought
to enhance dopaminergic neurotransmission for exhibit-
ing their wake-promoting effects and since altered
dopaminergic contents are reported in the brains of both
human and canine narcolepsy [43,44], it seems plausible
that the activity of both of these genes is intimately con-
nected to the extensive daytime sleepiness in several spe-
cies. Further functional characterization of TAC1, PENK
and SOCS2 in relationship to the deficiency of hypocretin
signalling, as well as to the downstream effect and symp-
toms of the disease, will be an important future challenge.
Future research should also address the question as to
whether the activity of these genes are modified in
humans suffering from narcolepsy as well, possibly iden-
tifying common molecular alterations associated with
similar symptoms.BMC Neuroscience 2007, 8:34 http://www.biomedcentral.com/1471-2202/8/34
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Methods
Animals
Brain samples from six narcoleptic Doberman pinschers
homozygous for the canarc-1  mutation and their six
healthy heterozygous siblings were used (Figure 1). The
dogs were bred at Stanford University housed in individ-
ual cages (1.0 × 1.8 m) at the Department of Comparative
Medicine Research Animal Facility, where temperature
(22–24°C), humidity (40%), and the light:dark cycle (12
h:12 h) were maintained at constant conditions. The phe-
notype of all homozygous and heterozygous animals was
investigated by studying behavioral responses after treat-
ment with cataplexy-inducing compounds, including
physostigmine (acetylcholinesterase inhibitor; 100 µg/kg,
i.v.), prazosin (alpha-1 antagonist; 0.6 mg/kg, p.o.), quin-
pirole (D2 autoreceptor agonist; 6 µg/kg, i.v.), BHT920
(D2 autoreceptor agonist with alpha-2 activity; 3 µg/kg,
i.v.). The effects of these compounds were examined
between 5 and 7 months of age: drug challenges were
given every week in the following sequence: saline, pra-
zosin, quinpirole, BHT920, saline (1st session), physostig-
mine plus prazosin, physostigmine plus quinpirole,
physostigmine plus BHT920, physostigmine plus
BHT920 (2nd session). In homozygous animals, phys-
ostigmine, prazosin, quinpirole and combinations elic-
ited cataplexy whereas heterozygous animals were not
affected by single drug challenges but showed brief epi-
sodes of cataplexy after drug combinations. The effects of
these drug challenges were brief and did not last more
than 24 hr [4]. After this period, no animal was used for
any pharmacological experiments and all animals were
sacrificed 9 months following the end of drug exposures.
The animals were euthanized at a mean age of one year
and four months by a lethal dose of pentobarbital
between 7:00 am to 9:00 am. Brains were removed imme-
diately  post mortem, frozen by immersion in liquid 2-
methylisobutane (-40°C), and stored at -80°C. All exper-
iments were carried out in strict accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
Tissue samples and isolation of nucleic acids
From each brain, tissue samples from the regions of
hypothalamus, amygdala and pons were morphologically
identified with the support of a pathologist at the Swedish
National Veterinary Institute, dissected and subsequently
homogenized in TRIzol® reagent (Invitrogen). The sam-
ples were then processed as previously described [10,11].
Briefly, frozen tissue of approximately 0.2 g of each region
was homogenized in TRIzol®  and RNA was extracted
according to the manufacturers' instructions (Invitrogen™,
Life Technologies). The concentration of extracted RNA
was measured using a NanoDrop® ND-1000 instrument
(NanoDrop Technologies, USA) and mRNA was isolated
with PolyATtract® mRNA Isolation Systems (Promega).
Microarray hybridization
RNA pools from hypothalamus, amygdala and pons were
prepared using six individuals from each group: narcolep-
tic (N) and heterozygous (H) siblings. The samples were
nearly balanced with respect to sex ratio and the age of the
animals. Each pool consisted of equal amounts of total
RNA from each animal. From each RNA pool mRNA was
isolated with PolyATtract®  mRNA Isolation Systems
(Promega) and used in a reverse transcription reaction
with either the Micromax TSA Labeling and detection kit
(hypothalamus pool) or the Genisphere® Labeling and
Detection Kit, 3DNA Array 900 Cy3/Cy5. For each brain
region the cDNA pools from the two groups were pair-
wise hybridized to slides printed with 29 760 human
cDNA clones with an average length of ~400 bp (Microar-
ray resource centre, Royal Technical Institute, Sweden).
Each hybridization was repeated with the dye assignment
reversed (dye-swap replication). Hypothalamus pools
were hybridized on four arrays, whereas sample pools
from amygdala and pons were hybridized on two arrays
respectively. Hybridizations were performed according to
the manufacturers' protocols (Micromax TSA and Geni-
sphere® Inc. USA) with modified temperature (50°C) to
allow for better cross hybridization between dog and
human sequences.
The microarrays were scanned at 10 µm resolution using
a GenePix 4100A scanner (Axon Instruments, Inc.). Spots
on the resulting images were quantified with the software
package GenePix Pro 5.0 (Axon Instruments, Inc.). The
mean intensity of the Cy5-labelled sample (R) and the
Cy3-labelled reference (G) were used to calculate the log
transformed ratio between the sample and the reference
for each spot: M = log2 (R/G).
Real-time RT-PCR assay
Quantification of mRNA levels in brain autopsies was per-
formed using real-time RT-PCR (qPCR) as described pre-
viously [45]. Briefly, mRNA was isolated from each
individual sample with PolyATtract® mRNA Isolation Sys-
tems (Promega) and converted to cDNA using TaqMan®
Gold RT-PCR Kit (Applied Biosystems). Preparations of
21 µl qPCR reactions using SYBR®Green PCR Core Rea-
gents kit (Applied Biosystems) were added to plates where
4 µl of all 36 samples were randomly distributed in dupli-
cates on a 96-well plate. The use of 96-well replicate plates
allowed for independent analysis of all samples from all
individuals. All qPCRs were done for each individual sam-
ple independently without prior pooling. The sequences
of the human clones present in the arrays were used for
BLAST searches on the dog genome, and the homologous
dog sequence was used to design primers for qPCR. The
accession numbers for the dog ESTs used for designing
primers (human clone ID within parenthesis) were:
LOC477889 (IMAGE:2017204), LOC475239BMC Neuroscience 2007, 8:34 http://www.biomedcentral.com/1471-2202/8/34
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(IMAGE:784179), LOC481278 (IMAGE:430318),
LOC481142 (IMAGE:782789), XM_535531.2
(IMAGE:1046495), LOC487562 (IMAGE:646753),
DR106036.1 (IMAGE:287646) and DN750458.1
(IMAGE:131073). Sequences of all primers are available
upon request. Primers were also designed for the reference
genes GAPDH (Glyceraldehyde-3-phosphate dehydroge-
nase) and ACTB (Actin, beta). The PCR reactions were run
on an ABI PRISM®  7000 Sequence Detector System
(Applied Biosystems).
Microarray data analysis
Prior to the analysis of the microarray data, we used a
robust scatter plot smoother (Proc Loess, SAS v8.2) to per-
form a sub-array intensity-dependent normalization of M,
with the smoothing parameter set to 40% [46]. All spots
with a mean spot intensity below the local median back-
ground were excluded from the analysis. A total of 15227
clones gave signals above background on all amygdala
and pons arrays and at least three of the four hypothala-
mus arrays. To identify genes that were differentially
expressed between the two groups of dogs, in one or more
regions of the brain, we analyzed the signals from the
clones with an ANOVA model (Proc GLM, SAS v8.2),
which included the factor "status" (narcoleptic or hetero-
zygote) and the interaction "status*region", (region hav-
ing the levels: amygdala, pons and hypothalamus).
However, due to the experimental design, the statistical
model for the experiments was parameterized as a regres-
sion model [47]. We penalized the F-ratio by adding a
constant (a0) to the denominator and choose a0 to be the
90th percentile of the mean square errors of all clones
[48,49]. We considered penalized F-ratios for both the dif-
ference between the groups of dogs and across all regions,
and for the interaction between this difference and brain
region, to be indicative of a differential expression. The
empirical false discovery rate (FDR) for lists of selected
clones was determined for a suit of penalized F-ratios by
permutation of residuals (1000 permutations), and
clones with a penalized F-ratio above 5, corresponding to
a FDR of 0.29 were regarded as differentially expressed
between narcoleptic and healthy dogs.
Real-time RT-PCR data analysis
The qPCR data was analyzed with a mixed ANCOVA
model, (Proc Mixed, SAS v8.2) and empirical p-values
were obtained after 10,000 permutations of variables "sta-
tus" between siblings and "region" within individual. Dif-
ferences between status (narcoleptic versus heterozygote)
were assessed using the between-animal variability,
whereas the effects of region and the interaction between
region and status were assessed using the variability of
samples within animal. In order to account for variation
in mRNA quantity, the geometric mean of the expression
of the two reference genes ACTB  and  GAPDH  were
included as covariates in the model [50,51]. In a prelimi-
nary analysis neither sex nor litter affected the expression
levels of the investigated genes, and therefore these varia-
bles were not included in the final model. Since the resid-
uals from the models deviated significantly from
normality, empirical p-values were derived by 10,000 per-
mutations, where "status" was permuted between siblings
and "region" was permuted within individual.
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